Biolife Solutions opens new facility in Amsterdam

By Rachel Arthur contact

- Last updated on GMT

Pic:Biolife Solutions
Pic:Biolife Solutions

Related tags: CAR-T, cell and gene therapy, Amsterdam, BioLife Solutions

Biolife Solutions and its subsidiary SciSafe have opened a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, located next to Schiphol Airport.

The new facility, which is already partially contracted to an undisclosed anchor pharmaceutical customer, will include a CAR-T cell storage suite to support development of emerging CAR-T cell treatments, such as for rare cancers and diseases.

It offers a freezer farm of 300+ Stirling Ultracold ultra-low temperature (ULT) freezers for biopreservation of temperature sensitive biologic material.

Schiphol is one of Europe’s biggest airports and a transportation hub for the region. SciSafe says its clients are expanding their existing partnerships to use the new Amsterdam facility as a way of improving global access to biologic therapies.  

“Our SciSafe team has extensive industry experience and expertise in establishing cGMP compliance of cold chain distribution, biostorage protocols, equipment management and sample management,”​ says Michael Rice, Chairman and CEO.

“We plan to fully leverage our facilities to showcase our tools and services portfolio and to create Centers of Excellence for education and training on CGT bioprocessing workflows.”​     

Bothell, Washington-headquartered Biolife is a supplier of bioproduction tools for cell and gene therapies (GCT): with a portfolio across manufacturing, storage, distribution and thawing. It acquired biostorage services company SciSafe in 2020, followed by the acquisition of ultra-low temperature freezer company Stirling Ultracold this year.

Its cold storage solutions protect biologic materials in conditions ranging from +70°C to -196°C.

Related news

Show more

Related suppliers

Follow us

Products

View more

Webinars